Literature DB >> 7705835

Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families.

M Rossel1, I Schuffenecker, M Schlumberger, C Bonnardel, E Modigliani, P Gardet, J Navarro, Y Luo, G Romeo, G Lenoir.   

Abstract

Multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B), and familial medullary thyroid carcinoma (FMTC) are three dominantly inherited disorders linked to the same disease locus on chromosome 10. Two types of germline mutation of the RET proto-onco-gene, which codes for a transmembrane tyrosine kinase, are associated with MEN 2. Missense mutations at cysteine residues in the extra-cytoplasmic domain are exclusively associated with MEN 2A and FMTC. In MEN 2B patients, a single point mutation at codon 918 has recently been characterized, leading to the replacement of a methionine by a threonine within the RET tyrosine kinase domain. We now report the identification of a mutation at codon 918 in the germline of 16 patients out of 18 unrelated MEN 2B families analyzed. In these families we have been able to demonstrate that, in five cases, the mutation arose de novo, and that, in one kindred, it was coinherited with the disease. These results indicate that a unique mutation at codon 918 of the RET gene is the most prevalent genetic defect causing MEN 2B, but also that rare MEN 2B cases are associated with different mutations yet to be defined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705835     DOI: 10.1007/bf00208964

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  20 in total

1.  Simplified mammalian DNA isolation procedure.

Authors:  P W Laird; A Zijderveld; K Linders; M A Rudnicki; R Jaenisch; A Berns
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

2.  Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.

Authors:  M Takahashi; Y Buma; T Iwamoto; Y Inaguma; H Ikeda; H Hiai
Journal:  Oncogene       Date:  1988-11       Impact factor: 9.867

Review 3.  Genetic aspects of multiple endocrine neoplasia.

Authors:  R N Schimke
Journal:  Annu Rev Med       Date:  1984       Impact factor: 13.739

4.  Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma.

Authors:  B D Nelkin; Y Nakamura; R W White; A C de Bustros; J Herman; S A Wells; S B Baylin
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

5.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

6.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

Authors:  C Eng; D P Smith; L M Mulligan; M A Nagai; C S Healey; M A Ponder; E Gardner; G F Scheumann; C E Jackson; A Tunnacliffe
Journal:  Hum Mol Genet       Date:  1994-02       Impact factor: 6.150

7.  Linkage of the multiple endocrine neoplasia type 2B gene (MEN2B) to chromosome 10 markers linked to MEN2A.

Authors:  R A Norum; R G Lafreniere; L W O'Neal; T F Nikolai; J P Delaney; J C Sisson; H Sobol; G M Lenoir; B A Ponder; H F Willard
Journal:  Genomics       Date:  1990-10       Impact factor: 5.736

8.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.

Authors:  K M Carlson; S Dou; D Chi; N Scavarda; K Toshima; C E Jackson; S A Wells; P J Goodfellow; H Donis-Keller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Exon structure and flanking intronic sequences of the human RET proto-oncogene.

Authors:  I Ceccherini; R Bocciardi; Y Luo; B Pasini; R Hofstra; M Takahashi; G Romeo
Journal:  Biochem Biophys Res Commun       Date:  1993-11-15       Impact factor: 3.575

10.  Expression of the c-ret proto-oncogene during mouse embryogenesis.

Authors:  V Pachnis; B Mankoo; F Costantini
Journal:  Development       Date:  1993-12       Impact factor: 6.868

View more
  5 in total

1.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.

Authors:  Sina Jasim; Anita K Ying; Steven G Waguespack; Thereasa A Rich; Elizabeth G Grubbs; Camilo Jimenez; Mimi I Hu; Gilbert Cote; Mouhammed Amir Habra
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

2.  Single oligoarray-based detection of specific M918T mutation in RET oncogene in multiple endocrine neoplasia type 2B.

Authors:  R A Pacheco-Rivera; E Hernández-Zamora; B González-Yebra; K Beattie; R Maldonado-Rodríguez; J C Santiago-Hernández; M E Medrano-Ortiz de Zárate; M Salcedo
Journal:  Clin Exp Med       Date:  2011-01-21       Impact factor: 3.984

3.  Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine.

Authors:  I Schuffenecker; N Ginet; D Goldgar; C Eng; B Chambe; A Boneu; C Houdent; D Pallo; M Schlumberger; C Thivolet; G M Lenoir
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

4.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Authors:  F Lesueur; M Corbex; J D McKay; J Lima; P Soares; P Griseri; J Burgess; I Ceccherini; S Landolfi; M Papotti; A Amorim; D E Goldgar; G Romeo
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

5.  Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

Authors:  F M Michiels; S Chappuis; B Caillou; A Pasini; M Talbot; R Monier; G M Lenoir; J Feunteun; M Billaud
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.